A Phase IV, Multicenter, Randomized, Single-blinded (Evaluator), Active-controlled, Parallel Study for Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Moderate to Severe Dry Eye Disease Patients
Conditions: Dry Eye; Dry Eye Syndromes Interventions: Drug: TJO-018; Drug: Cyclosporine Ophthalmic Emulsion 0.05%; Drug: TJO-018 + Cyclosporine Ophthalmic Emulsion 0.05% Sponsor: Taejoon Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials